Qinghao Biejia Decoction Combined with Auricular Acupoint Seed Embedding in Improving TCM Syndromes and Sleep Parameters in Perimenopausal Insomnia Patients.
{"title":"Qinghao Biejia Decoction Combined with Auricular Acupoint Seed Embedding in Improving TCM Syndromes and Sleep Parameters in Perimenopausal Insomnia Patients.","authors":"Ying Wu, Wei Hu, Lili Yao, Min Cui","doi":"10.1080/15402002.2026.2657918","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of QinghaoBiejia Decoction (QBD) combined with auricular acupoint seed embedding (AASE) in improving Traditional Chinese Medicine (TCM) syndromes and sleep parameters in perimenopausal insomnia patients.</p><p><strong>Methods: </strong>This singlecenter, randomized, parallel-group controlled trial enrolled 160 perimenopausal women aged 45-55 years with insomnia. Participants were randomly allocated (1:1:1:1) to four groups: (1) QBD plus AASE, (2) QBD alone, (3) AASE alone, or (4) sleep hygiene education control. The intervention period was 8 weeks with 12-week follow-up. Primary outcome was Pittsburgh Sleep Quality Index (PSQI) change from baseline. Secondary outcomes included polysomnography parameters, TCM syndrome scores, Insomnia Severity Index (ISI), Menopause Rating Scale (MRS), hormone levels, and heart rate variability.</p><p><strong>Results: </strong>The combination group showed significantly greater PSQI reduction (-5.82 ± 2.14) compared to QBD alone (-3.76 ± 1.98), AASE alone (-3.21 ± 2.05), and control (-1.43 ± 1.76) groups (all <i>p</i> < .001). Objective sleep parameters including total sleep time (TST), sleep efficiency (SE), and wake after sleep onset (WASO) improved significantly in the combination group. TCM syndrome scores decreased by 68.4% in the combination group versus 45.2%, 41.8%, and 18.6% in other groups respectively. The clinical effective rate was 90.0% for combination therapy. Adverse events were minimal (3.3%) and mild.</p><p><strong>Conclusion: </strong>QBD combined with AASE demonstrates superior efficacy compared to monotherapy in treating perimenopausal insomnia, significantly improving both subjective and objective sleep parameters while ameliorating TCM syndromes. This integrative approach offers a safe and effective treatment option for perimenopausal women with insomnia.</p>","PeriodicalId":55393,"journal":{"name":"Behavioral Sleep Medicine","volume":" ","pages":"573-590"},"PeriodicalIF":2.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioral Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15402002.2026.2657918","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the efficacy and safety of QinghaoBiejia Decoction (QBD) combined with auricular acupoint seed embedding (AASE) in improving Traditional Chinese Medicine (TCM) syndromes and sleep parameters in perimenopausal insomnia patients.
Methods: This singlecenter, randomized, parallel-group controlled trial enrolled 160 perimenopausal women aged 45-55 years with insomnia. Participants were randomly allocated (1:1:1:1) to four groups: (1) QBD plus AASE, (2) QBD alone, (3) AASE alone, or (4) sleep hygiene education control. The intervention period was 8 weeks with 12-week follow-up. Primary outcome was Pittsburgh Sleep Quality Index (PSQI) change from baseline. Secondary outcomes included polysomnography parameters, TCM syndrome scores, Insomnia Severity Index (ISI), Menopause Rating Scale (MRS), hormone levels, and heart rate variability.
Results: The combination group showed significantly greater PSQI reduction (-5.82 ± 2.14) compared to QBD alone (-3.76 ± 1.98), AASE alone (-3.21 ± 2.05), and control (-1.43 ± 1.76) groups (all p < .001). Objective sleep parameters including total sleep time (TST), sleep efficiency (SE), and wake after sleep onset (WASO) improved significantly in the combination group. TCM syndrome scores decreased by 68.4% in the combination group versus 45.2%, 41.8%, and 18.6% in other groups respectively. The clinical effective rate was 90.0% for combination therapy. Adverse events were minimal (3.3%) and mild.
Conclusion: QBD combined with AASE demonstrates superior efficacy compared to monotherapy in treating perimenopausal insomnia, significantly improving both subjective and objective sleep parameters while ameliorating TCM syndromes. This integrative approach offers a safe and effective treatment option for perimenopausal women with insomnia.
期刊介绍:
Behavioral Sleep Medicine addresses behavioral dimensions of normal and abnormal sleep mechanisms and the prevention, assessment, and treatment of sleep disorders and associated behavioral and emotional problems. Standards for interventions acceptable to this journal are guided by established principles of behavior change. Intending to serve as the intellectual home for the application of behavioral/cognitive science to the study of normal and disordered sleep, the journal paints a broad stroke across the behavioral sleep medicine landscape. Its content includes scholarly investigation of such areas as normal sleep experience, insomnia, the relation of daytime functioning to sleep, parasomnias, circadian rhythm disorders, treatment adherence, pediatrics, and geriatrics. Multidisciplinary approaches are particularly welcome. The journal’ domain encompasses human basic, applied, and clinical outcome research. Behavioral Sleep Medicine also embraces methodological diversity, spanning innovative case studies, quasi-experimentation, randomized trials, epidemiology, and critical reviews.